We are live on ! Find out more
ENTX icon

Entera Bio

12 hedge funds and large institutions have $14.2M invested in Entera Bio in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 12 → 12 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

2.47% less ownership

Funds ownership: 19.65% → 17.19% (-2.5%)

92% less capital inflows, than outflows

Capital inflows: $147K | Capital outflows: $1.87M

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.19%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
–
Reduced
4
Closed
4
Calls
$550​K
Puts
–
Net Calls
+$550​K
Net Calls Change
-⁠$36​K

ENTX Hedge Fund Activity: Q1 2022 in Review

12 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q1 2022, worth a combined $14.2M — down 11% from $15.9M a quarter earlier.

Fund positioning in ENTX was balanced in Q1 2022: 4 funds opened new positions, 4 closed out, 0 added to existing stakes and 4 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $111K. The largest seller was ARK Investment Management, cutting an estimated $1.65M.

  • 12 institutional investors held Entera Bio (ENTX) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $14.2M of Entera Bio stock for Q1 2022, down 11% quarter-over-quarter.
  • 4 funds opened new Entera Bio positions in Q1 2022 and 4 closed out, a net change of 0 holders.
  • The largest Entera Bio buyer in Q1 2022 was Millennium Management, an estimated $111K added.
  • The largest Entera Bio seller in Q1 2022 was ARK Investment Management, an estimated $1.65M sold.

Based on aggregated 13F filings for Q1 2022.